Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

23.10.17	Eli Lilly Plans To Invest $72 Mln In Insulin Manufacturing Project - Quick Facts (RTTNews)
23.10.17	Lilly announces $72 million investment in diabetes manufacturing in Indianapolis (PR Newswire)
18.10.17	Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines (PR Newswire)
16.10.17	Lilly Declares Fourth-Quarter 2017 Dividend (PR Newswire)
16.10.17	Eli Lilly: REVEL Data Show Efficacy Of Ramucirumab Plus Docetaxel - Quick Factsz (RTTNews)
16.10.17	Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis (PR Newswire)
14.10.17	Indigenous groups, science community, marine industry, and government partners make progress in protecting endangered killer whale population (PR Newswire)
12.10.17	Lilly's Verzenio Gets FDA Priority Review Designation For Advanced Breast Cancer (RTTNews)
12.10.17	FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer (PR Newswire)
11.10.17	CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4 (RTTNews)
10.10.17	Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer (PR Newswire)
10.10.17	InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board (PR Newswire)
09.10.17	New Drugs Approved In September (RTTNews)
06.10.17	Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer (PR Newswire)
06.10.17	SK Planet Japan to Launch Geo-Targeted Crypto-Currencies to Attract Booming Chinese Tourists (PR Newswire)
05.10.17	U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent (PR Newswire)
05.10.17	Additional Delivery of Insulin Ready for Distribution in Puerto Rico (PR Newswire)
05.10.17	MDA Completes Acquisition of DigitalGlobe, Creates Industry Leader in Satellite Systems, Earth Imagery, Geospatial Solutions and Analytics (PR Newswire)
04.10.17	Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes (PR Newswire)
03.10.17	Arbor Pharmaceuticals, LLC & Debiopharm International annoncent la commercialisation de Triptodur™, formulation triptoreline 6 mois, pour le traitement des patients atteints de puberte precoce... (PR Newswire)
02.10.17	NAFTA, retail innovation, brand resilience and entrepreneurial retailer leadership examined on Oct 12 at Retail West 2017 (PR Newswire)
02.10.17	Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement (PR Newswire)
29.09.17	Lilly Promotes Josh Smiley To SVP And CFO (RTTNews)
29.09.17	Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing (PR Newswire)
29.09.17	FDA Okays Lilly's Breast Cancer Drug Verzenio (RTTNews)
28.09.17	Elanco Celebrates 10 Years of Volunteerism During Global Day of Service (PR Newswire)
25.09.17	Geisinger, Boehringer Ingelheim Announce Collaboration - Quick Facts (RTTNews)
25.09.17	Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications,... (PR Newswire)
14.09.17	Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib (RTTNews)
14.09.17	Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
13.09.17	Biosynthesis Technology Could Transform Cannabinoid Production (PR Newswire)
13.09.17	Biosynthesis Technology Could Transform Cannabinoid Production (PR Newswire)
12.09.17	Lilly: Jardiance Tablets Reduces Cardiovascular Death Risks In Type 2 Diabetes (RTTNews)
12.09.17	Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control (PR Newswire)
11.09.17	Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress (PR Newswire)
10.09.17	Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer (PR Newswire)
09.09.17	IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine (PR Newswire)
08.09.17	Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study (RTTNews)
08.09.17	IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine (PR Newswire)
07.09.17	US-Pharmariese Eli Lilly will 3500 Stellen streichen (AWP) Der US-Pharmakonzern Eli Lilly will im Rahmen eines Sparprogramms in grossem Stil Mitarbeiter entlassen.» mehr
07.09.17	Lilly Plans To Cut About 3,500 Jobs Globally (RTTNews)
07.09.17	Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth (PR Newswire)
06.09.17	Landmark M&A Deals Continue to Shape Big Pharma (PR Newswire)
06.09.17	Landmark M&A Deals Continue to Shape Big Pharma (PR Newswire)
06.09.17	Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC) (PR Newswire)
30.08.17	MÄRKTE USA/Anleger begrüssen starke US-Wirtschaft (Dow Jones)
30.08.17	Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018 (RTTNews)
30.08.17	Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 (PR Newswire)
29.08.17	Eli Lilly To Present Data From Phase 3 Studies Of Abemaciclib, Ramucirumab (RTTNews)
29.08.17	New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’281.00	1.10 %	K V
Kuehne+Nagel Int	203.30	0.35 %	K V
Alcon	76.56	0.31 %	K V
Holcim	89.00	0.16 %	K V
Logitech Intl	74.86	0.00 %	K V
UBS Group	27.89	-0.99 %	K V
Sika	223.80	-1.06 %	K V
Swiss Re	129.75	-1.67 %	K V
Nestle	73.74	-1.97 %	K V
Givaudan	3’979.00	-2.02 %	K V

mehr

12:26		Börse Europa in Grün: Euro STOXX 50 steigt mittags
12:26		Börse Zürich: SMI präsentiert sich leichter
09:29		Verluste in Europa: Euro STOXX 50 beginnt die Mittwochssitzung im Minus
09:29		Verluste in Zürich: SMI beginnt Mittwochshandel im Minus
09:29		Optimismus in Frankfurt: DAX zum Handelsstart fester
09:29		Pluszeichen in Frankfurt: Anleger lassen LUS-DAX zum Start steigen
17.12.24		Schwache Performance in New York: S&P 500 beendet den Handel im Minus
17.12.24		Pfizer-Aktie unverändert: Umsatz auf Vorjahreshöhe für 2025 geplant

12:26

Börse Europa in Grün: Euro STOXX 50 steigt mittags

12:26

Börse Zürich: SMI präsentiert sich leichter

09:29

Verluste in Europa: Euro STOXX 50 beginnt die Mittwochssitzung im Minus

09:29

Verluste in Zürich: SMI beginnt Mittwochshandel im Minus

09:29

Optimismus in Frankfurt: DAX zum Handelsstart fester

09:29

Pluszeichen in Frankfurt: Anleger lassen LUS-DAX zum Start steigen